Microbot Medical stock: New patent adds to LIBERTY IP portfolio
Published on 11/10/2026 at 22:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPatent expands commercialization groundwork
- Microbot Medical said the Canadian Intellectual Property Office granted a patent on November 5, 2026.
- The company continues building infrastructure to support broader commercialization of the LIBERTY Endovascular Robotic System.
Microbot Medical said on Thursday, November 5, 2026, that the Canadian Intellectual Property Office granted the company a patent as it continues building infrastructure for future commercialization expansion. The announcement was published in a Microbot Medical press release.
Patent expands commercialization groundwork
The company develops and distributes the LIBERTY Endovascular Robotic System. Microbot said the Canadian grant adds to its intellectual property portfolio while commercialization continues across the United States and international markets.
The announcement adds an intellectual property milestone to Microbot's broader commercial strategy. Earlier company updates highlighted customer expansion, international distribution and efforts to establish the infrastructure needed for wider adoption of LIBERTY.
Microbot Medical stock trades in euros
Microbot Medical stock traded at 0.94 euros on Lang & Schwarz at 10:51 p.m. CET on Tuesday, November 10.
Microbot Medical at a glance
- Company: Microbot Medical Inc.
- ISIN: US59503A2042
- Ticker: MBOT
- Home exchange: Nasdaq
- Lang & Schwarz price: 0.94 euros at 10:51 p.m. CET on November 10, 2026
For broader market context, investors can follow the S&P 500 alongside company-specific developments.
Further updates on the company and its technology are available in more news and analyses on Microbot Medical stock.
